Lv4
538 积分 2023-03-01 加入
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
56分钟前
待确认
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
1小时前
待确认
Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies
5天前
已完结
Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies
5天前
已完结
Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
6天前
已完结
Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma
7天前
已完结
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
8天前
已完结
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
8天前
已完结
Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy
15天前
已完结
AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage
15天前
已完结
皖公网安备34019202002308
